Citation: Tk. Jellison et al., Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam, PHARMACOTHE, 21(2), 2001, pp. 142-148
Authors:
Tam, VH
McKinnon, PS
Levine, DP
Brandel, SM
Rybak, MJ
Citation: Vh. Tam et al., Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: Case report and review, PHARMACOTHE, 20(9), 2000, pp. 1116-1119
Authors:
Neuhauser, MM
McKinnon, PS
Hershberger, E
Rybak, MJ
Citation: Mm. Neuhauser et al., Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function, PHARMACOTHE, 20(5), 2000, pp. 554-561
Citation: Ps. Mckinnon et Mm. Neuhauser, Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections, PHARMACOTHE, 19(6), 1999, pp. 724-733
Authors:
Karam, CM
McKinnon, PS
Neuhauser, MM
Rybak, MJ
Citation: Cm. Karam et al., Outcome assessment of minimizing vancomycin monitoring and dosing adjustments (vol 19, pg 257, 1999), PHARMACOTHE, 19(5), 1999, pp. 674-674
Authors:
Murry, KR
McKinnon, PS
Mitrzyk, B
Rybak, MJ
Citation: Kr. Murry et al., Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside, PHARMACOTHE, 19(11), 1999, pp. 1252-1260